Centers of Excellence for Translational Research (CETR) (U19 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications from single institutions or a consortium of institutions to participate in the Centers for Excellence in Translational Research (CETR) program. This program will support multidisciplinary translational research Centers focused on generating, validating, and advancing medical countermeasures against bacteria or fungi listed in the NOFO with known and emerging resistance to current therapies.


  • Letter of Intent Due Date(s): 30 days prior to the application due date

  • Application Due Date: April 29, 2024

RFA-AI-23-065 Expiration Date April 30, 2024

Agency Website

Areas of Interest

The objective of this NOFO is to support a program of multi-project translational research Centers focused on advancing potential MCM candidates (therapeutics, immunotherapeutics, vaccines, vaccine technologies, and in vitro diagnostics) for known or emerging AMR bacteria and fungi beyond discovery through preclinical development.NIAID encourages Centers focused on development of MCMs that are effective against a variety of pathogens and toxins, technologies that can be widely applied to improve classes of products, and platforms that can reduce the time and cost of creating new products. For this NOFO, "preclinical development" is defined as all activities including hit-to-lead candidate identification through Investigational New Drug (IND) application enabling.

Each Center will be organized around a specific major objective, theme or program goal, that addresses development of MCMs for AMR bacteria and/or fungi. NIAID anticipates considerable variety among Center themes and objectives, which can range for example, from the development of countermeasures targeting a specific resistant pathogen or group of resistant pathogens, to the development of new technologies or platforms that target a wide array of these pathogens selected from the list below. Because FDA authorization of MCMs identified through these programs should be a long-term goal, each Center should consider and address anticipated regulatory barriers for the targeted countermeasure or technology, particularly for new classes of MCMs for which there are no precedents for FDA approval. Consistent with these goals, a Product Development Strategy, which should include Milestones and Product Development Plans, must be included in the Overall component of each application, with the exception of those focusing upon early translational studies in fungal pathogens.



Amount Description

Application budgets are not expected to exceed $5 million in direct costs per year and should reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Funding Type





Medical - Translational

External Deadline

April 29, 2024